KREBS BIOCHEMICALS & INDUSTRIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 65.89 INR | -4.55% |
|
-9.22% | -15.89% |
Valuation
| Fiscal Period: Marzo | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 2,255 | 1,929 | 1,474 | 1,743 | 3,092 | 1,216 |
| Enterprise Value (EV) 1 | 2,813 | 2,290 | 2,135 | 2,848 | 4,522 | 3,049 |
| P/E ratio | -12.7 x | -9.64 x | -5.11 x | -6.15 x | -6.94 x | -4.92 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 6.89 x | 4.13 x | 4.55 x | 3.31 x | 5.27 x | 2.33 x |
| EV / Revenue | 8.6 x | 4.9 x | 6.59 x | 5.41 x | 7.71 x | 5.85 x |
| EV / EBITDA | -37.3 x | -23.6 x | -11.4 x | -16.5 x | -13.4 x | -19.7 x |
| EV / FCF | -271 x | 61.4 x | -5.73 x | -6.33 x | -13.6 x | -9.07 x |
| FCF Yield | -0.37% | 1.63% | -17.5% | -15.8% | -7.35% | -11% |
| Price to Book | -12.7 x | -13.5 x | -5.9 x | -4.08 x | -4.12 x | -1.22 x |
| Nbr of stocks (in thousands) | 13,744 | 16,631 | 18,001 | 19,621 | 21,561 | 21,561 |
| Reference price 2 | 164.1 | 116.0 | 81.90 | 88.85 | 143.4 | 56.40 |
| Announcement Date | 17/08/18 | 31/08/19 | 01/09/20 | 31/08/21 | 06/09/22 | 04/09/23 |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Marzo | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 327.2 | 467.4 | 324 | 526.8 | 586.9 | 521.3 |
| EBITDA 1 | -75.37 | -97.18 | -187.2 | -172.9 | -337.8 | -154.7 |
| EBIT 1 | -114.9 | -139 | -231.4 | -221.5 | -394.4 | -218.5 |
| Operating Margin | -35.11% | -29.74% | -71.42% | -42.05% | -67.2% | -41.9% |
| Earnings before Tax (EBT) 1 | -178.2 | -200.1 | -288.7 | -283.6 | -445.3 | -246.9 |
| Net income 1 | -178.2 | -200.1 | -288.7 | -283.6 | -445.3 | -246.9 |
| Net margin | -54.48% | -42.81% | -89.12% | -53.83% | -75.87% | -47.36% |
| EPS 2 | -12.97 | -12.03 | -16.04 | -14.45 | -20.65 | -11.45 |
| Free Cash Flow 1 | -10.37 | 37.31 | -372.5 | -449.9 | -332.2 | -336.1 |
| FCF margin | -3.17% | 7.98% | -115% | -85.41% | -56.61% | -64.46% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 17/08/18 | 31/08/19 | 01/09/20 | 31/08/21 | 06/09/22 | 04/09/23 |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 558 | 361 | 660 | 1,104 | 1,430 | 1,833 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -7.403 x | -3.71 x | -3.528 x | -6.388 x | -4.234 x | -11.85 x |
| Free Cash Flow 1 | -10.4 | 37.3 | -373 | -450 | -332 | -336 |
| ROE (net income / shareholders' equity) | 219% | 125% | 147% | 83.7% | 75.6% | 28.3% |
| ROA (Net income/ Total Assets) | -5.79% | -6.48% | -10.5% | -9.45% | -14.1% | -7.49% |
| Assets 1 | 3,079 | 3,089 | 2,757 | 3,001 | 3,153 | 3,299 |
| Book Value Per Share 2 | -12.90 | -8.590 | -13.90 | -21.80 | -34.80 | -46.10 |
| Cash Flow per Share 2 | 0.3000 | 10.40 | 0.1000 | 0.3600 | 0.0500 | 0.0400 |
| Capex 1 | 43.1 | 43.4 | 94.1 | 255 | 271 | 152 |
| Capex / Sales | 13.16% | 9.28% | 29.05% | 48.41% | 46.14% | 29.07% |
| Announcement Date | 17/08/18 | 31/08/19 | 01/09/20 | 31/08/21 | 06/09/22 | 04/09/23 |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -15.89% | 17.01M | |
| +19.62% | 43.27B | |
| +24.52% | 22.92B | |
| +20.29% | 15.43B | |
| +7.48% | 12.95B | |
| +42.51% | 11.83B | |
| -8.84% | 6.91B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +13.13% | 5.55B |
- Stock Market
- Equities
- KREBSBIO Stock
- Financials Krebs Biochemicals & Industries Limited
